IMedPub, 2013. — 136 p. In view of the growing prevalence of AD worldwide, there is an urgent need for the development of better diagnostic tools and more effective therapeutic interventions. Indeed, much work in this field has been done during last decades. As such, a major goal of current clinical research in AD is to improve early detection of disease and presymptomatic...
Springer-Verlag London, 2007. — 298 p. Abeta Peptide and Alzheimer’s Disease summarizes current knowledge of beta-amyloid peptide (Aß) and its role as the major culprit in Alzheimer’s Disease (AD), shown by recent advances in genetics and brain biochemistry. Written by leaders in the industrial and academic world specializing in this rapidly moving area, the book covers...
5th Ed. — Purdue University Press, 2016. — 265 p. — ASIN B01NCLB1J7, ISBN 1557537607. The beloved best seller has been revised and expanded for the fifth edition. Jolene Brackey has a vision: that we will soon look beyond the challenges of Alzheimer's disease to focus more of our energies on creating moments of joy. When people have short-term memory loss, their lives are made...
4th edition. — Purdue University Press, 2007. — 331 p. Jolene Brackey has a vision. A vision that will soon look beyond the challenges of Alzheimer's disease and focus more of our energy on creating moments of joy. When a person has short-term memory loss, his life is made up of moments. But if you think about it, our memory is made up of moments, too. We are not able to create...
Penguin Random House, 2017. — 308 p. The instant New York Times and Wall Street Journal bestseller A groundbreaking plan to prevent and reverse Alzheimer's Disease that fundamentally changes how we understand cognitive decline. Everyone knows someone who has survived cancer, but until now no one knows anyone who has survived Alzheimer's Disease. In this paradigm shifting book,...
2nd edition. — Elsevier, 2016. — 283 p. — ISBN: 978-0-323-28661-9 Now presented in full color, this updated edition of Memory Loss, Alzheimer's Disease, and Dementia is designed as a practical guide for clinicians that delivers the latest treatment approaches and research findings for dementia and related illnesses. Drs. Budson and Solomon — both key leaders in the field —...
Elsevier, 2018. — 186 p. — ISBN: 978-0-323-54425-2. Get a thorough, expert overview of the many key facets of chronic traumatic encephalopathy (CTE) with this concise, practical resource by Drs. Andrew E. Budson, Ann C. McKee, Robert C. Cantu, and Robert A. Stern. This easy-to-read reference is based on lectures from Boston University’s Alzheimer’s Disease Center’s November...
Springer, 1992. — 165 p. Any mention of the relationship, still poorly understood, between body (or brain) and mind invariably invokes the name of Descartes, who is often thought of as the father of modern philosophy and perhaps of neurophilosophy. Although a native of the heart of France (the region around Tours), Rene Descartes travelled widely, as everyone knows, especially...
CRC Press, 2003. — 179 p. Beta-secretase. M. Citron Alpha-secretases. S. Ishiura ADAM 10/alpha secretase and presenilins/gamma secretase in APP processing and notch signaling. D. Hartmann Gamma-secretase and presenilin. M. Wolfe Biochemistry of gamma-secretase (tentative title). S. Sinha Presenilin and intracellular protein transport Degradation of Abeta by neprilysin. T.C....
Elsevier, 2016. — 207 p. Consequences of Intracellular Amyloid in Alzheimer’s Disease addresses one of the more currently unresolved aspects confounding Alzheimer’s research, the significance of intraneuronal amyloid. It seeks to explain some of the unresolved questions concerning intracellular amyloid and its origin, entry, and toxicity. Following up on Dr. D’Andrea’s first...
First Interact, 2009. — 332 p. ISBN: 2754010580. The book is in French. - L'ouvrage La maladie d'Alzheimer pour les Nuls présente cette maladie neurodégénérative du tissu cérébral à tous ceux qui voudraient en savoir plus. Proches des malades, personnel soignant, membres de la famille y trouveront de nombreuses réponses, pour accompagner et comprendre le malade au quotidien....
Nova Science Publishers, Incorporated, 2017. — 305 p. The brain is an extremely complex organ that defines your uniqueness. As you age, though, your brain may be susceptible to a terrible disease. Alzheimer's disease is the third biggest killer in the developed world after cancer and heart disease. It is considered an irreversible, progressive brain disorder that slowly erases...
Informa Healthcare, 2007. — 159 p. — ISBN: 978 0 415 39045 3 The last 20 years have brought unprecedented new knowledge to our understanding of Alzheimer's disease (AD) and for the first time, approved symptomatic treatments. Authored by one of the world's leading authorities on the management of AD and related dementias, this highly illustrated Atlas of Alzheimer’s Disease...
Nova Biomedical , 2008. — 318 p. — ISBN: 978-1604569919 Alzheimer's disease (AD) is characterized by the deposition into the brain of amyloid peptide, which originates a cascade of inflammatory events leading eventually to neuronal death. This book gives information about MCI as prodromal Alzheimer's disease (AD), and discusses the main known pathological mechanisms at the...
Nova Science Publishers, 2016. — 115 p. — (Neurology – Laboratory and Clinical Research Developments) — ISBN: 978-1-63484-032-3 Alzheimer’s disease (AD) is the most common form of senile dementia worldwide. Anosognosia, a deficit in self-awareness, is recognized as one of the core symptoms of Alzheimer’s disease dementia, in which self-awareness gradually deteriorates with...
Academic Press, 2018. — 103 p. — ISBN: 978-0-12-815392-5. This book provides a practical and easy-to-use guide for researchers in EEG signal processing techniques, Alzheimer’s disease, and dementia diagnostics. The book examines different features of EEG signals used to properly diagnose Alzheimer’s Disease early, presenting new and innovative results in the extraction and...
Springer, 2008. — 179 p. — ISSN: 1862-2461, ISBN: 978-3-540-74228-9. DOI 10.1007/978-3-540-74229-6. Therapeutic Approaches for the Treatment of Alzheimer's Disease. Cholinesterase Inhibitors. Beyond Cholesterol: Statin Benefits in Alzheimer's Disease. PPARg Agonists for the Treatment of Alzheimer's Disease. Metal Complexing Agents for the Treatment of Alzheimer's Disease. GSK3...
Royal Society of Chemistry, 2010. — 343 p. Emerging Drugs and Targets for Alzheimer's Disease collects some of the most outstanding examples of new drugs currently under pharmaceutical development or new targets in the validation process that will reach the Alzheimer's drug market over the next few years as disease modifying drugs. Written by a team of distinguished experts...
Royal Society of Chemistry, 2010. — 327 p. Alzheimer's disease is the most prevalent neurodegenerative disorder in the elderly. A recent study from the Bloomberg School of Public Health recently estimated that over 26 million people were living with the disease in 2006 and that the global prevalence of the disease will grow to 106 million by 2050. By that time, 43 per cent of...
Wiley, 2019. — 532 p. — ISBN: 978-1-119-35679-0. Understanding the impact of diet, exercise, genetics, and hormones on the risk and development of Alzheimer’s and other neurogenerative diseases Diet is widely known to impact on neurological function. Nevertheless, academic texts discussing this relationship are relatively few in number. This book therefore fills an important...
Springer, 2014. — 43 p. A lot of research on biomarkers for Alzheimer is being done in the last few decades. The aim of these studies is to find some method to ease the diagnosis of Alzheimers as early as possible. Such methods are a range of blood or CSF tests on one hand and several types of neuroimaging scans on the other. Many of the images coming both from laboratory and...
IOS Press, 2017. — 420 p. — (Advances in Alzheimer's Disease 3). Alzheimer’s disease is one of the biggest emerging public health problems in the world. Although the last four decades have yielded important insights into the pathogenesis of Alzheimer’s disease, its cause is still unclear, and if it is not discovered the world will face an unprecedented healthcare problem by the...
Springer, 2019. — 247 p. This book describes the precise mechanisms by which insulin resistance and diabetes mellitus (DM) act as risk factors for Alzheimer’s disease (AD). It opens by discussing the de novo synthesis of insulin in the brain and its functional significance with regard to glucose metabolism and maintenance of neuronal function in the brain. The epidemiological...
Academic Press, 2019. — 71 p. — ISBN: 978-0-12-816412-9. This book discusses the latest information on recent theranostic avenues for both the diagnosis and treatment of Alzheimer’s patients. It presents the pros and cons of the probable mechanistic role of nanoparticles in crossing the blood-brain barrier and improving disease symptoms. Finally, it highlights the merits of...
HarperOne, 2017. — 368 p. — ISBN: 978-0062666475. “The Alzheimer’s Solution, is the best, most professionally informed book of its kind for this much feared disease…the protocol recommended by Drs. Dean and Ayesha Sherzai is a very important message to convey to the public. Please, read this book.” (—T. Colin Campbell, coauthor of The China Study) In this thorough, thoughtful,...
Springer, 2007. — 296 p. Alzheimer’s Disease: Advances in Genetics, Cellular and Molecular Biology provides exciting, comprehensive and up-to-date summaries of the most important recent advances in the genetic, molecular, biochemical, and cell biological studies of AD. The studies and advances described in this volume will help to accelerate the process of rational drug...
Workman Publishing Company, 2012. — 288 p. Want to keep Alzheimer's at bay for years--ideally, forever? Prevention is the way, and this is the guide. Now in paperback and updated throughout, "The Alzheimer's Prevention Program" is essential for everyone with a family history of Alzheimer's, and for the 80 million baby boomers who worry whenever they forget someone's name. It's...
For Dummies, 2011. — 384 p. An estimated 4 million people are living with Alzheimer’s Disease (AD) in America today, with approximately 370,000 new cases diagnosed every year. AD patients live anywhere from 5 to 20 years after their diagnosis; and their inability to care for themselves grows more dramatic as the disease progresses, creating profound implications for their...
Bentham Science Publishers, 2017. — 207 p. Frontiers in Clinical Drug Research - Alzheimer Disorders is a book series concerned with Alzheimer's disease (AD) that causes dementia, or loss of brain function. The disease affects the parts of the brain that deal with memory, thought, and language. Chapters in each volume focus on (Alzheimer Disorders) drug research with special...
2nd edition. — Oxford University Press, 2017. — 138 p. — (Oxford Neurology Library). — ISBN 978–0–19–877980–3. Dementia disorders: an overview Pathophysiology of Alzheimer’s disease Epidemiology of Alzheimer’s disease Clinical course of Alzheimer’s disease Atypical presentations of Alzheimer’s disease Diagnosing Alzheimer’s disease in clinical practice Disclosing the diagnosis...
CRC Press, 2012. — 301 p. — ISBN: 9781439827086. In recent years, a tremendous amount of effort has been focused on better understanding the fundamentals of Alzheimer’s disease (AD) to facilitate early and accurate diagnosis and appropriately targeted therapeutic treatments. Alzheimer’s Disease: Targets for New Clinical, Diagnostic, and Therapeutic Strategies provides a...
Springer, 2013. — 230 p. — (Caregiving: Research • Practice • Policy) — ISBN: 978-1-4614-5334-5 Assisting someone with Alzheimer’s disease or another illness that causes dementia is incredibly demanding and stressful for the family. Like many disabling conditions, Alzheimer’s disease leads to difficulty or inability to carry out common activities of daily life, and so family...
Comments